24 results about "Atp production" patented technology

The invention relates to a diatomic iron-iron site nano-enzyme constructed by relieving oxidative stress and cartilage degeneration and used for targeted osteoarthritis treatment. According to the invention, a nitrogen-doped porous carbon anchored diatomic iron nano enzyme catalyst (Fe2-NCs) with Fe-Fe dimer coordination is developed by using a'subject-object 'strategy. The Fe2-NCs protect cartilage cells from oxidative stress induced apoptosis by modulating ROS and active nitrogen species (RNS) and promoting O2 release. In addition, Fe2-NCs restores mitochondrial function by inhibiting NOX4 expression, improving ATP production, and normalizing COXIV levels. In an in-vivo OA model, the Fe2-NCs can reduce the expression of a pro-inflammatory medium COX-2 through an NF-kappa B signal channel, inhibit the up-regulation of MMP-13 and delay the degradation of type II collagen. The invention provides a new theoretical framework and methodological approach for the treatment of osteoarthritis, and has important clinical and scientific significance.

The present invention provides a human T cell lacking human leukocyte antigen (HLA) class I molecule and containing an exogenous ST6GALNAC6 gene, which has the following characteristics (a) and / or (b):(a) CD62L-positive and CD45RA-positive(b) a total ATP production rate of a human T cell-containing cell population of 400 pmol / min / 105 cells or more and a mitochondrial spare respiratory capacity of 40 pmol / min / 105 cells or more, 5-6 days after the application of T cell proliferation stimulation to the cell population. According to the present invention, a low-immunogenic human T cell that can remain stably in the body for a long period of time after transplantation is provided, and the development of a versatile CAR-T cell or TCR-T cell for allotransplantation becomes possible by using the human T cell.

To provide agents for promoting epidermal keratinocyte growth, filaggrin mRNA expression, serine palmitoyltransferase mRNA expression, involucrin expression or ATP production by finding substances having excellent activity in promoting epidermal keratinocyte growth, filaggrin mRNA expression, serine palmitoyltransferase mRNA expression, involucrin expression or ATP production.SOLUTION: An epidermal keratinocyte growth promoting agent of the invention comprises one or more effective ingredients selected from the group consisting of 2-ketoglutaric acid, 2-isopropyl malate, inosine 5'-monophosphoric acid, succinic acid, malic acid and pyruvic acid. Also, a filaggrin mRNA expression promotor, a serine palmitoyltransferase mRNA expression promotor, an involucrin expression promotor of the invention comprise, as an effective ingredient, 2-ketoglutaric acid. Further an ATP production promotor of the invention comprises 2-isopropyl malate as an effective ingredient.SELECTED DRAWING: None

This invention relates to the field of cosmetic compositions, and more specifically to a synergistic anti-aging composition involving energy metabolism and autophagy, its preparation method, and its application. The composition comprises sea buckthorn fruit extract, trehalose, and a cosmetically acceptable polyol carrier. This invention pioneers a betaine-trehalose-NADES extraction system, achieving low-temperature, high-efficiency extraction while preserving the heat-sensitive active ingredients of sea buckthorn. Trehalose possesses both extraction and autophagy activation effects. A selective separation strategy achieves a balance between efficacy, compliance, and process simplicity. The green, circular process reduces costs and is environmentally friendly. Through the synergistic effect of sea buckthorn fruit extract and trehalose, the composition enhances mitochondrial membrane potential, increases ATP production, inhibits excessive activation of the mTOR pathway, and promotes LC3-II conversion, thus synergistically combating skin aging from multiple targets including cellular energy metabolism, signaling pathways, and autophagy.

A micronutrient composition comprises of several combinations of individual ingredients in forming Mix 11, G12, G13 and core mix formulation. Core mix contains magnesium citrate, alpha-Ketoglutaric acid, L-Citrulline and Taurine. The Mix 11, G12 and G13 contains Magnesium Citrate, Alpha-Ketoglutaric Acid, Niacinamide, L-Glutamine, L-Citrulline, Sodium Pyruvate, Succinic acid, Vitamin B complex, Taurine, L-Cysteine, L-Methionine, L-Ascorbic Acid, Coenzyme Q10 or combination thereof. A method of administering and treating a specific disease which is due to one of an oxidative stress, impaired mitobiogenesis and ATP production in a mammal is disclosed.

The present invention relates to a method for activating the mitochondrion, wherein mainly negative charges and reactive oxygen species are supplied to the mitochondrion from the outside via a negative charge and reactive oxygen species delivery unit to serve as material for the mitochondrial redox reaction. A calcium ion channel stimulation unit stimulates an in vivo calcium ion to transport the protein across the calcium on the inner mitochondrial membrane into a mitochondrial matrix space, such that the influx of calcium ions promotes mitochondrial depolarization and increases the activity of mitochondrial oxidative phosphorylation. This enhances mitochondrial activation and ATP production.

The present invention relates to the control and enhancement of energy production of mitochondria through maximizing electron transfer efficiency using natural pigments and light. The composition for mitochondrial modification according to the present invention, which comprises two or more natural pigments selected from the group consisting of □-carotene, anthocyanin, and chlorophyll a as active ingredients, and the mitochondria modified by mixing these active ingredients have the effects of increasing ATP production and decreasing ROS production, and thus can be usefully used as a health functional food composition for improving exercise function and fatigue. Moreover, the effect of promoting the production of mitochondrial energy and preventing oxidative damage by light irradiation, can be used for the prevention and treatment of diseases related to mitochondrial dysfunction.

The invention belongs to the technical field of biological medicines, and particularly discloses a polypeptide for protecting lung vascular endothelial cells and relieving lung injury and application of the polypeptide. The polypeptide is Humanin-G (HNG), and the amino acid sequence of the polypeptide is MAPRGFSCLLLLTGEIDLPVKRRA. The polypeptide is targeted to mitochondria of pulmonary vascular endothelial cells, provides protection from energy supply and cell survival roots, and has profound significance in improving functions of the pulmonary vascular endothelial cells and reducing the death rate of sepsis-induced acute lung injury (ALI). Researches show that when the polypeptide is used in the acute injury stage, lung inflammation of a model animal can be relieved by 25%-50%, the lung injury HE score can be reduced by about 50%, pulmonary edema can be relieved by about 30%, mitochondrial functions can be recovered by about 70%, the ATP yield can be increased by 30%, and the effect is excellent. Therefore, the invention provides a brand new strategy for maintaining the mitochondrial homeostasis by using the polypeptide so as to relieve lung injury.

This invention relates to a mitochondrial composite nanosystem DTPS@Mito targeting lung inflammation, comprising a mitochondrial core and a functionalized lipid material DSPE-TK-PEG2000-SA modified on its surface. DSPE acts as a hydrophobic anchor inserted into the mitochondrial outer membrane, PEG2000 provides hydrophilicity and biocompatibility, ketithiothiol bonds serve as ROS-responsive linkers, and sialic acid targets the head group to specifically bind to E-selectin, which is highly expressed at the inflammatory site. The DTPS@Mito particles have a diameter of approximately 832 nm, maintaining intact mitochondrial morphology and protein composition. In vitro experiments show that it significantly inhibits the expression of inflammatory factors, reduces ROS levels, restores ATP production, and regulates mitochondrial dynamics. In vivo experiments show that it has enhanced retention and accumulation capacity in the lungs of ARDS mice, significantly alleviating lung inflammation, tissue damage, and oxidative stress, and reducing hyaline membrane formation. This invention achieves the synergistic integration of three major functions: mitochondrial transplantation, targeted delivery, and antioxidation, and can be used to prepare drugs for the treatment of acute respiratory distress syndrome.

This invention relates to the field of cell biology, and discloses a culture medium and method for inducing physiological myocardial hypertrophy based on carnosine. The culture medium for inducing physiological myocardial hypertrophy contains carnosine. By introducing an appropriate concentration of carnosine into a cardiomyocyte system, this invention can induce a series of phenotypic changes in cardiomyocytes related to physiological myocardial hypertrophy, including increased cardiomyocyte area, increased mitochondrial number, enhanced oxidative metabolic capacity, and increased ATP production capacity. These changes can improve the energy metabolism level of cardiomyocytes, thus providing a new technical solution for studying myocardial adaptive remodeling.

This invention relates to the field of cell culture technology, and discloses a method for culturing NK cells and its applications. When NK cells enter a hypoxic environment, not only do their cytotoxic activity and proliferative capacity rapidly decline, but they also experience metabolic disorders such as impaired mitochondrial function, insufficient ATP production, and abnormal accumulation of reactive oxygen species (ROS), leading to functional failure and limiting their application in tumor therapy. Existing technologies mainly rely on constant or single-stage hypoxia induction, failing to improve the insufficient hypoxia adaptation of NK cells at the metabolic level. Therefore, this invention provides a method that uses repeated acclimatization culture with gradually decreasing oxygen concentration to allow NK cells to gradually adapt to the metabolic demands of a hypoxic environment. NK cells cultured using this method exhibit a more stable metabolic state and superior cytotoxic activity in a hypoxic environment, significantly enhancing their anti-tumor efficacy and solving the problem of metabolic imbalance and rapid functional loss of NK cells in the hypoxic tumor microenvironment in existing technologies.

The present application relates to a novel micropeptide MP29 and a use thereof and relates to a use of the micropeptide in the preparation of a reagent or drug for preventing, treating, or alleviating diseases related to abnormal mitochondrial energy metabolism in cells, wherein the diseases include Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, aging, photoaging, fatty liver disease, liver fibrosis, liver cirrhosis, liver cancer, diabetic nephropathy, cardiovascular diseases such as heart failure, etc. By means of endogenous overexpression or exogenous synthesis, the reducing equivalents NADH in the tricarboxylic acid cycle are up-regulated to promote intracellular ATP production, thereby significantly enhancing the proliferation of high-energy-demanding cardiac cells and brain tissue cells, or suppressing oxidative damage and apoptosis of cells in Alzheimer's disease models and Parkinsonism, or alleviating hypertrophy and aging of myocardial cells in heart failure models, or ameliorating the photodamage of cells in photoaging models. These results indicate that the micropeptide MP29 has an application value in preventing or treating diseases related to abnormal mitochondrial energy metabolism.

The present invention relates to a method and system for producing adenosine triphosphate (ATP) through an acid / aldehyde-ATP (AAA) cycle in an electrochemical cell.

This invention discloses the application of NT5C1A as a therapeutic target for myocardial ischemia-reperfusion injury, belonging to the field of biomedical technology. Through proteomics screening and in vitro and in vivo experiments, this invention is the first to discover and demonstrate that NT5C1A is upregulated in the pathological process of MIRI, and is a key upstream factor regulating the AMPK / SIRT1 / PGC-1α signaling pathway. Overexpression of NT5C1A can effectively activate this pathway, synergistically regulating multiple downstream pathological processes: promoting the expression of mitochondrial fusion proteins Mfn-2 and OPA1, inhibiting the expression of the splitting protein DRP1; significantly promoting ATP production and improving energy metabolism disorders; and regulating the balance of apoptosis-related protein Bax / Bcl-2 expression, inhibiting cardiomyocyte apoptosis, ultimately reducing myocardial damage, improving myocardial function, and reducing the infarct area. This invention provides a new target and strategy for the precise intervention of MIRI.

The application discloses a polyphosphate kinase and application thereof in improving ATP production, and belongs to the technical field of genetic engineering.The polyphosphate kinase disclosed by the application is PePPK, PsPPK, RbPPK or RrPPK, and the amino acid sequence is shown as SEQ ID NO.5-8.The polyphosphate kinase disclosed by the application can improve ATP production, and can synthesize glutathione and 3'-phosphoadenosine-5'-phosphosulfate.

This invention relates to the field of biomedical technology, and more particularly to the use of a combination of RVX208 and temozolomide for the treatment of glioblastoma. It also relates to the use of RVX208 to resensitize temozolomide-resistant cancers to temozolomide treatment. The use of at least one of RVX208, a pharmaceutically acceptable salt of RVX208, a solvate of RVX208, a hydrate of RVX208, a polymorph of RVX208, an isomer of RVX208, a prodrug form of RVX208, and temozolomide in the preparation of a glioblastoma therapeutic agent. RVX208 inhibits the transcriptional activity of various genes related to cell cycle progression and proliferation maintenance by inhibiting BET family proteins or other target molecules, leading to cell cycle arrest, inhibition of cell proliferation, and induction of programmed cell death. RVX208 also interferes with the transcriptional expression of genes related to mitochondrial homeostasis regulation, resulting in a decrease in mitochondrial membrane potential and reduced ATP production, thus enabling RVX208 to disrupt mitochondrial function in GBM cells and produce a synergistic antitumor effect with temozolomide.

The invention discloses polyphosphate kinase and application thereof in increasing ATP (adenosine triphosphate) output, and belongs to the technical field of gene engineering. The polyphosphate kinase disclosed by the invention is PePPK, PsPPK, RbPPK or RrPPK, and the amino acid sequence of the polyphosphate kinase is as shown in SEQ ID NO. 5-8. The polyphosphokinase disclosed by the invention can be used for increasing the generation amount of ATP (adenosine triphosphate) and synthesizing glutathione and 3 '-phosphoadenosine-5'-phosphoryl sulfuric acid.

The present application relates to an anti-aging composition for improving cardiovascular function and a preparation method and application thereof, and the composition comprises L-ergothioneine, honokiol, quercetin and coenzyme Q10. The present application creatively designs an anti-aging composition for improving cardiovascular aging, which improves cardiovascular aging from four dimensions of "myocardial energy supply + anti-hypertrophy + endothelial protection + anti-oxidation". Coenzyme Q10 can restore myocardial mitochondrial ATP production, honokiol can reverse myocardial hypertrophy through NAD+ deacetylase, quercetin can improve endothelial function and reduce blood pressure, and L-ergothioneine can protect vascular endothelial cells from oxidative damage and inhibit the formation of ox-LDL. Through research, it is found that the four can cooperate and synergize with each other, and can jointly play an excellent role in improving cardiovascular aging, and achieve multiple protection for cardiovascular aging.

The invention discloses radix ophiopogonis powder capable of improving mitochondrial activity and resisting aging and a preparation method and application of the radix ophiopogonis powder, and relates to the technical field of radix ophiopogonis products. The prepared radix ophiopogonis powder can effectively improve mitochondrial membrane potential, activate a mitochondrial compound I, increase ATP (adenosine triphosphate) generation and reduce ROS (reactive oxygen species) level, remarkably recover heart beat output and realize cross-model mitochondrial activation in a zebra fish myocardial injury model, and can remarkably improve activity of a nematode compound I, nematode movement ability and nematode life in a nematode model. Meanwhile, the compound has good safety in a human body, and can improve mitochondrial activity and delay telomere shortening after being orally taken. The composition is used for human skin, has excellent moisturizing, barrier repairing and anti-oxidation effects, and has the functions of remarkably improving mitochondrial activity and resisting aging.

The invention provides a method for activating granulate bodies, which mainly comprises the following steps of: supplying negative charges and active oxygen to the granulate bodies from the outside through a negative charge and active oxygen supply unit so as to serve as raw materials for redox of the granulate bodies; the calcium ion channel promoting unit promotes the calcium ions in the body to enter the matrix space of the granulonema through calcium transport proteins on the granulonema inner membrane, so that the internal flow of the calcium ions can promote the depolarization of the granulonema, and the oxidative phosphorylation activity of the granulonema is improved. Thus, granulocyte activation and ATP production are enhanced.

The present invention relates to a compound of formula (I) or an enantiomer, diastereomer, N-oxide, solvate or pharmaceutically acceptable salt thereof. The present invention further relates to a compound of formula (I) for use in a method of preventing and / or treating a disease or condition, in particular cancer.

This invention discloses the application of a peptide SRD in the preparation of drugs for treating acute kidney injury, belonging to the field of biomedical technology. In an in vitro H2O2-induced oxidative stress injury experiment on renal tubular epithelial cells, this invention found that peptide SRD treatment significantly reduced the apoptosis rate of renal tubular cells damaged by oxidative stress, promoted ATP production, and restored mitochondrial respiratory chain function. In an animal model of ischemia-reperfusion-induced acute kidney injury, mice with acute kidney injury injected via the tail vein showed significantly decreased serum creatinine and blood urea nitrogen levels. Pathological observation revealed a significant reduction in the degree of renal tubular injury, a lower histological score, and a significant downregulation of KIM-1, an indicator of the degree of renal tubular injury. This indicates that the antioxidant peptide SRD can improve mitochondrial function in renal tubular cells, effectively reduce renal tubular cell damage, promote the repair of renal tubular epithelial cells in acute kidney injury (AKI), effectively improve renal function, and has a good therapeutic effect on acute kidney injury.

The application relates to application of an anti-aging composition in preparation of a product for improving muscle attenuation, and the composition comprises pyrroloquinoline quinone, ergothioneine, coenzyme Q10 and ginsenosides. The application creatively designs an anti-aging composition and applies the anti-aging composition to improve muscle attenuation, and the anti-aging composition delays muscle attenuation through a triple mechanism of 'energy recovery + mitochondrial amplification + oxidation protection': ginsenoside CK recovers muscle energy sensing and fatty acid oxidation through AMPK, coenzyme Q10 directly improves muscle mitochondrial ATP production, pyrroloquinoline quinone promotes muscle mitochondrial quantity amplification, and ergothioneine can protect muscle fibers from oxidative damage. The four components complement each other and play a synergistic role in delaying muscle attenuation on multiple levels, forming a systematic intervention scheme.

The invention relates to a skin care composition for external use. The skin care composition for external use comprises nicotinamide and one or more resveratrol salicylate. The composition increases the level of energy in epidermal keratinocytes while mitigating oxidative damage associated with increased ATP production due to administration of nicotinamide. The performance of AQP-3, CLDN-1, and CLDN-4 is also increased, thereby improving barrier function in the skin and increasing moisture retention. Preferably, the composition is used as a mixture or emulsion in the form of cream, lotion, essence or gel.